Efficacy of the Apitherapy in the treatment of recalcitrant localized plaque psoriasis and evaluation of Tumor Necrosis Factor-Alpha (TNF-a) serum level: Double blind randomized clinical trial.
Phase 3
Completed
- Conditions
- ocalized psoriasisInflammatory and Immune System - Autoimmune diseasesLocalized psoriasisSkin - Dermatological conditions
- Registration Number
- ACTRN12613001028796
- Lead Sponsor
- Faculty of Medicine, Suez Canal University, prof. Atef Elakhras
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
*Patients diagnosed as recalcitrant localized psoriasis.
*Patients aged 18 -60 years.
*Both genders.
*Stopping any topical or systemic treatment for psoriasis during the last 2 months.
Exclusion Criteria
*Patient who had any allergic disorder.
*Patient who had reactions to bee stings.
*Patient who are responding well to conventional treatment.
*Pregnancy and lactation.
*Systemic diseases such as diabetes and cardiac diseases
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the therapeutic potential effect of Bee venom in recalcitrant localized Psoriasis, by assessing Physician Global Assessment (PGA) before and after treatment[To evaluate the therapeutic potential effect of Bee venom in recalcitrant localized Psoriasis at the end of 3 months of treatment];To evaluate the therapeutic potential effect of Bee venom in recalcitrant localized Psoriasis at the end of 3 months of treatment. By assessing with physician global assessment (PGA).[To evaluate the therapeutic potential effect of Bee venom in recalcitrant localized Psoriasis at the end of 3 months of treatment]
- Secondary Outcome Measures
Name Time Method To detect the effect of Bee venom on the serum level of Tumor necrosis factor alpha (TNF-a).[To detect the effect of Bee venom on the serum level of Tumor necrosis factor alpha (TNF-a).by measuring serum level of (TNF-a) at the beginning and 12th week of treatment via polystyrene microplate ELISA]